GlassScriptPhysician profile
Ingrid Lewis
NPI 1639660046
$1,854.18
in general payments reported to CMS, 2019-2025
18 companies · $854 in 2025
The $854 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $114 · 2023: $485 · 2024: $400 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $368.47 | 2022-2025 | Sublocade |
| Abbvie INC. | $228.56 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $219.18 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $214.75 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Dexcom, INC. | $166.76 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Exact Sciences Corporation | $134.01 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $93.50 | 2023-2025 | Rexulti |
| Abbott Laboratories | $77.84 | 2023 | Diamondback Peripheral |
| Coloplast Corp | $74.99 | 2024 | |
| Novo Nordisk INC | $60.31 | 2023-2025 | Wegovy |
| Lundbeck LLC | $54.89 | 2025 | Rexulti, Vyepti |
| Phadia US INC. | $36.07 | 2022-2024 | Immunocap |
| Echosens North America, INC. | $29.61 | 2025 | Fibroscan |
| Alkermes, INC. | $20.63 | 2024 | Vivitrol |
| Orexo US, INC. | $19.23 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $19.21 | 2024 | Uptravi, Opsumit |
| Braeburn INC. | $18.77 | 2024 | Brixadi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.40 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.